Treatment with Obecabtagene Autoleucel Results in Durable Response Among Adults with Relapsed or Refractory B-Cell ALL By Ogkologos - December 12, 2024 740 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the FELIX study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Poherdy Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with Solid Cancers FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer MOST POPULAR ASCO20 Virtual Research Round Up Podcast: Breast Cancer, Sarcoma, and Supportive... July 21, 2020 Nivolumab Appears to Boost Cure Rate in Advanced Hodgkin Lymphoma November 14, 2024 Football Player Scores 8 Touchdowns the Day After His Mom Dies... November 17, 2021 FDA Grants Accelerated Approval to Melphalan Flufenamide for Relapsed or Refractory... April 20, 2021 Load more HOT NEWS Selpercatinib Shows Durable Efficacy in RET Fusion–positive NSCLC Trastuzumab Deruxtecan Demonstrates Efficacy in HER2-positive and HER2-low Advanced Gastric Cancer England moves to a single-dose HPV vaccine New on NCI’s Websites for September 2020
